<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7366108\results\search\drug\results.xml">
  <result pre="scientifically approved vaccines/drugs for COVID-19. Nonetheless, few broad-spectrum antiviral drugs," exact="azithromycin" post="were tested against COVID-19 in clinical trials, and finally,"/>
  <result pre="to wield anti-inflammatory and antifibrotic actions, stimulate the release of" exact="nitric oxide," post="and decrease blood pressure [43,44]. ACE-2 has shown a"/>
  <result pre="Clinical phase (sample size) Findings Status Clinical trial identifier 1." exact="Hydroxychloroquine" post="Block viral entry by inhibiting glycosylation of host receptors,"/>
  <result pre="IV(11) No Result Posted for this study Completed NCT04291729 6." exact="Methylprednisolone" post="Immunomodulatory effect Phase 2 &amp;amp; Phase 3(80) No Result"/>
  <result pre="is an antiviral drug, act as nucleotide analog, specifically an" exact="adenosine" post="analogue, which inserts into viral RNA chains, causing their"/>
  <result pre="and treat scurvy, a disease caused by a lack of" exact="vitamin C" post="National Clinical Trial Identifier:(NCT04264533) 9. Combination of Azithromycin and"/>
  <result pre="of vitamin C National Clinical Trial Identifier:(NCT04264533) 9. Combination of" exact="Azithromycin" post="and Hydroxychloroquine Azithromycin: Antibacterial with some in-vitro activity against"/>
  <result pre="C National Clinical Trial Identifier:(NCT04264533) 9. Combination of Azithromycin and" exact="Hydroxychloroquine" post="Azithromycin: Antibacterial with some in-vitro activity against some viruses"/>
  <result pre="contribute to an antiinflammatory response in patients with viral infections" exact="Azithromycin" post="is clinically used as adjunctive therapy to management of"/>
  <result pre="other inflammatory conditions National Clinical Trial Identifier:(NCT04327401), (NCT04344730), (NCT04348305) 12." exact="Nitric oxide" post="Selective pulmonary vasodilator; may be useful in the adjunctive"/>
  <result pre="a potential complication of COVID-19 National Clinical Trial Identifier:(NCT04306393) 13." exact="Ruxolitinib" post="Janus kinase (JAK) 1 and 2 inhibitor; 7 may"/>
  <result pre="proinflammatory cytokines, including interferon, during viral infections such as COVID-19" exact="Ruxolitinib" post="is a clinically approved Janus-associated kinase (JAK) inhibitor with"/>
 </snippets>
</snippetsTree>
